RECURSION PHARMACEUTICALS, INC. RXRX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, RECURSION PHARMACEUTICALS, INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $74.7M, 100.0% of the filed sum (+26.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$74.7M100.0%+26.9% yoy
Members sum to the consolidated $74.7M for this period.
- Reportable Segment-$648M100.0%+35.3% yoy
Members sum to the consolidated -$648M for this period.
- License And Service$74.3M99.4%+27.0% yoy
- Grant$425K0.6%+21.1% yoy
Members sum to the consolidated $74.7M for this period.
- United States$39.3M52.7%-31.4% yoy
- United Kingdom$35.3M47.3%+3013.4% yoy
- Other countries$00.0%-100.0% yoy
Members sum to the consolidated $74.7M for this period.
- Reportable Segment$6.47M100.0%-56.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.